骨質疏鬆症藥物市場：按藥物類型、給藥途徑、分銷渠道、地區 - 規模、份額、前景和機會分析，2018-2026

骨質疏鬆症是一種與骨骼有關的疾病，它會削弱骨骼並增加骨折和骨折的風險。骨質疏鬆症的原因包括長期使用大劑量口服皮質類固醇、骨質疏鬆症家族史（尤其是父母有髖部骨折史）、低體重指數（BMI）以及大量飲酒和吸煙。骨質疏鬆症的治療包括骨折的預防和治療以及強健骨骼的藥物治療。治療通常涉及藥物，例如雙膦酸鹽，這是治療骨質疏鬆症最常用的藥物。此外，由於骨弱化雌激素水平降低，建議絕經後婦女接受激素治療。

市場動態

在預測期內，新型骨質疏鬆症治療藥物的批准和上市預計將顯著推動骨質疏鬆症治療市場的增長。例如，2019 年 10 月，美國食品藥品監督管理局（Food and Drug Administration）向生物技術公司 Pfenex 提交了 PF708 的新藥申請（NDA），以特立帕□注射液為參考藥物在 505（b）（2）監管途徑下。）宣布批准。 FDA 批准的 PF708 與特立帕□注射液一樣，適用於治療某些骨折高風險患者的骨質疏鬆症。

此外，2020 年 8 月，跨國製藥公司 Cadila Pharmaceuticals 宣佈在印度推出 Forteo 的骨質疏鬆症生物仿製藥 NuPTH。 Forteo 的生物仿製藥用於治療骨質疏鬆症和骨折風險增加的患者。 NuPTH 是一種生物仿製藥，旨在為骨質疏鬆症患者提供具有成本效益的解決方案，並將作為易於使用的預填充一次性筆進行銷售。

本研究的主要特點

• 它對全球骨質疏鬆症治療市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模（十億美元）和復合年增長率（CAGR%）。 .
• 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
• 該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球骨質疏鬆症治療市場主要參與者的概況。
• 本研究涵蓋的主要公司包括 Teva Pharmaceutical Industries Ltd.、DAIICHI SANKYO COMPANY, LIMITED、Amgen Inc.、Dr. Reddy's Laboratories Ltd.、Viatris Inc.、Ligand Pharmaceuticals Incorporated、Eli Lilly and Company、Asahi Kasei Corporation、F. Hoffmann-La Roche Ltd、EffRx Pharmaceuticals SA、Novartis AG、Merck & Co., Inc.、GSK plc 和 Pfizer Inc.
• 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球骨質疏鬆症治療市場》報告面向行業內的各種利益相關者，包括投資者和供應商、產品製造商、分銷商、新進入者和財務分析師。
• 通過用於分析全球骨質疏鬆症治療市場的各種戰略矩陣，利益相關者可以輕鬆做出決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第2章市場展望

• 舉報內容
  • 市場定義和範圍
• 執行摘要
  • 市場快照：按藥物類型
  • 按管理途徑劃分的市場概況
  • 市場快照：按分銷渠道
  • 市場概況：按地區劃分
• 連貫的機會圖 (COM)

第 3 章市場動態、監管和趨勢分析

• 市場動態
  • 驅動程序
  • 限制因素
  • 市場機會
• PEST 分析
• 管道分析
• 產品認證
• 產品發布
• 合作研究和收購
• 波特五力分析

第 4 章全球骨質疏鬆症藥物市場 - COVID-19 影響分析

• 整體影響
• 對供需的影響
• COVID-19 對市場的影響

第 5 章全球骨質疏鬆症藥物市場，按藥物類型，2017-2030 年

• 雙膦酸鹽
• 降鈣素
• 激素療法
• 選擇性雌激素受體調節劑 (SERM)
• 甲狀旁腺激素相關蛋白（PTHrP）類似物藥物
• Rank 配體 (RANKL) 抑製劑

第 6 章按給藥途徑分列的全球骨質疏鬆症藥物市場：2017-2030 年

• 口服劑
• 注入
• 其他

第 7 章。按分銷渠道分列的全球骨質疏鬆症藥物市場：2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 8 章按地區分列的骨質疏鬆症藥物全球市場，2017-2030 年

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海合會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第 9 章競爭格局

• Teva Pharmaceutical Industries Ltd.
• DAIICHI SANKYO COMPANY, LIMITED
• Amgen Inc.
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• Ligand Pharmaceuticals Incorporated
• Eli Lilly and Company
• Asahi Kasei Corporation
• F. Hoffmann-La Roche Ltd
• EffRx Pharmaceuticals SA
• Novartis AG
• Merck & Co., Inc.
• GSK plc.
• Pfizer Inc.

第10章 章節

• 調查手法
• 關於出版社

Osteoporosis is a bone related disease that weakens bones and increases the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis - particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. Osteoporosis treatment involves preventing and treating fractures and using medication to strengthen bones. The treatment usually includes medications such as Bisphosphonates that are the most common drugs prescribed for osteoporosis. Furthermore, hormone therapy treatment is recommended for post-menopausal women, as they experience a drop in the levels of estrogen, which weakens the bones.

Market Dynamics

Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over the forecast period. For instance, in October 2019, the U.S. Food and Drug Administration had announced the approval of the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with teriparatide injection as the reference drug to Pfenex, a biotechnology company. Like teriparatide injection, the FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.

Moreover, in August 2020, Cadila Pharmaceuticals, a multinational pharmaceutical company, had announced the launch of NuPTH an osteoporosis biosimilar of Forteo in India. The Forteo biosimilar is used for treatment of osteoporosis and in patients with increased risk of fracture. The biosimilar NuPTH aims to be a cost effective solution for patients with osteoporosis and will be sold as an easy to use, pre-filled disposable pen.

Key features of the study:

• This report provides in-depth analysis of the global osteoporosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global osteoporosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market

Detailed Segmentation:

• Global Osteoporosis Treatment Market, By Drug Type:
  • Bisphosphonates
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
• Global Osteoporosis Treatment Market, By Route of Administration:
  • Oral
  • Injectable
  • Others
• Global Osteoporosis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Osteoporosis Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• PEST Analysis
• Pipeline Analysis
• Product Approval
• Product Launch
• Collaboration-Acquisition
• Porter's Five Forces Analysis

4. Global Osteoporosis Treatment Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Osteoporosis Treatment Market, By Drug Type, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Bisphosphonates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
• Calcitonin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Selective Estrogen Receptor Modulators (SERMs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Rank Ligand (RANKL) Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Osteoporosis Treatment Market, By Route of Administration, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Osteoporosis Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Osteoporosis Treatment Market, By Region, 2017 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• DAIICHI SANKYO COMPANY, LIMITED
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Dr. Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ligand Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Asahi Kasei Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• EffRx Pharmaceuticals SA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us